US 12,453,726 B2
Methods of using factor B inhibitors
Irina Baltcheva, Oberwil (CH); Peter End, Oberwil (CH); and Julie Marie-Pomme Gabrielle Milojevic, Village Neuf (FR)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Mar. 5, 2024, as Appl. No. 18/595,759.
Application 18/595,759 is a continuation of application No. 17/376,483, filed on Jul. 15, 2021, granted, now 11,951,101.
Claims priority of provisional application 63/052,705, filed on Jul. 16, 2020.
Prior Publication US 2025/0025453 A1, Jan. 23, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/454 (2006.01); A61K 9/00 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 9/0053 (2013.01); A61P 7/06 (2018.01)] 49 Claims
 
1. A method of normalizing intravascular hemolysis (IVH) and/or extravascular hemolysis (EVH) in a subject in need thereof, the method comprising orally administering to the subject 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)piperidin-2-yl))benzoic acid or a pharmaceutically acceptable salt thereof, at a dose of about 200 mg twice daily (b.i.d.), thereby treating the subject, wherein the dosing amount refers to the anhydrous free base of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl) methyl)piperidin-2-yl))benzoic acid hydrochloride.